Realizing Promise of
Novel, Dynamically
Dual-Acting,
Broad-Spectrum
Immunomodulator
READ MORE »
Re-Thinking the Role of Immunomodulators: Dynamic Dual Action READ MORE » Seeking Balance
in COVID-19
Immune Storms
Powering
Relentless
Science
READ MORE »

Our Mission

To rescue, repair, and restore health in patients suffering
from debilitating and sometimes deadly diseases

Our Values

Power science
Strive relentlessly
Support each other and humankind

Read More »

Rescue, Repair, and Restore

EOM Pharmaceuticals’ goal is to rescue, repair, and restore health. We are focused on developing novel drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases.

Rethinking the Role of Immunomodulators
Watch how EOM Pharmaceuticals is rethinking the role of immunomodulators with its novel, dynamically dual-acting, broad-spectrum lead asset, EOM613, which can produce anti- and pro-inflammatory effects and could mitigate a hyperimmune reaction or “cytokine storm.”

Our Pipeline

EOM613

An investigational, novel, dynamically dual-acting immunomodulator. EOM613 is a peptide-nucleic acid solution and is believed to have both anti-inflammatory and pro-inflammatory broad-spectrum cytokine effects. In human cell culture studies, EOM613 demonstrated a unique “dynamic dual action” by suppressing or stimulating monocytes and macrophages depending on the activation state and environment of those key immune cells.1,2,3 It is hypothesized that this dynamic dual action may overcome a limitation of many approved immunomodulators that only reduce the inflammatory state, without achieving immune system balance.

EOM147

An investigational, broad-spectrum aminosterol with a unique intracellular mechanism for the treatment of retinal diseases. EOM147 is believed to affect multiple angiogenic growth factors such as VEGF, PdGF, and bFGF. This mechanism of action is uniquely differentiated from other retinal therapies that are only anti-VEGF and administered as an intraocular injection. The novel formulation, administererd as an eye drop, represents a potential breakthrough that does not require intraocular injection.

EOM147 is being developed as proprietary, newly reformulated eye drop, containing a steroid-polyamine conjugate compound with broad-spectrum antimicrobial activity and anti-angiogenic activity.

News Highlights

Press Release

EOM PHARMACEUTICALS ANNOUNCES FIRST PATIENTS DOSED IN R1: RESCUE PHASE 1/2A OPEN-LABEL TRIAL EVALUATING EOM613 IN HOSPITALIZED COVID-19 PATIENTS WITH SEVERE SYMPTOMS IN BRAZIL

August 24, 2021

MONTVALE, N.J. – August 24, 2021 — EOM Pharmaceuticals, Inc., a privately held, clinical-stage company, announced the first patients have been dosed in R1: RESCUE, a proof-of-concept Phase 1/2a open-label multicenter clinical study in Brazil to evaluate safety, tolerability, and preliminary efficacy of EOM613 in hospitalized COVID-19 infected patients with severe symptoms.

READ MORE »

Press Release

EOM PHARMACEUTICALS APPOINTS DRUG DEVELOPMENT VETERAN FRANK L. DOUGLAS, Ph.D., M.D., SCIENTIFIC ADVISOR

July 22, 2021

MONTVALE, N.J. – July 20, 2021 — EOM Pharmaceuticals, Inc., a privately-held, clinical-stage company, today announced the appointment of Frank L. Douglas, Ph.D., M.D., to Scientific Advisor. Dr. Douglas will be responsible for guiding the company’s clinical and scientific strategies for EOM lead candidate EOM613, as well as forming and chairing the EOM Scientific Advisory […]

READ MORE »